Skip to main content
. 2017 Jun 16;8(58):97920–97927. doi: 10.18632/oncotarget.18542

Table 2. Summary of PD-L1-negative HNSCC patient treated with cisplatin.

HNSCC type Sex/Age p16 status Brief history Baseline tissue Baseline PD-L1 Post-treatment tissue Post PD-L1
hypopharynx F/66 (−) Induction chemotherapy
 → definitive CCRT
 → salvage operation
Before induction chemotherapy, primary tumor (−) On salvage operation, recurred tumor (−)
Hypopharynx M/63 (−) Induction chemotherapy
→ definitive CCRT
→ salvage operation
Before induction chemotherapy. primary tumor (−) On salvage operation, recurred tumor (1+)
Pyriform sinus M/62 (−) Induction chemotherapy
 → definitive operation
  → post-RT
 → salvage operation
Before induction chemotherapy. primary tumor (−) On salvage operation, recurred tumor (1+)
Nasal cavity M/60 (−) Definitive CCRT
→ salvage operation
Before CCRT, primary tumor (−) On salvage operation, recurred tumor (1+)
Larynx M/66 (−) Definitive operation
 → post-CCRT
→ salvage operation
On definitive operation, primary tumor (−) On salvage operation, recurred tumor (1+)
Hypopharynx M/69 (−) Induction chemotherapy
 → definitive CCRT
→ salvage operation
Before induction chemotherapy. primary tumor (−) On salvage operation, recurred tumor (1+)

Abbreviation: HNSCC, head and neck squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; RT, radiotherapy.